Archive for the News Category

Ceapro Inc. Announces Publication of Positive Data from Functional Beverage Formulation Study in Journal of Functional Foods – Study successfully demonstrated the potential use of beta glucan and coenzyme Q10 as nutraceutical ingredients in functional beverages

EDMONTON, ALBERTA – June 27, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the publication of data from its functional beverage formulation study in the

Read more

Ceapro Announces Data from Avenanthramides Study Presented at the Nutrition 2018 Meeting – Results showed that oat avenanthramides supplementation reduce circulatory inflammation and inhibit expressions of chemokines and adhesion molecules

EDMONTON, ALBERTA – June 13, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that encouraging data from its study of avenanthramides in exercise-induced muscle inflammation were

Read more

Ceapro Announces Results of 2018 Shareholders’ Meeting

EDMONTON, ALBERTA – June 5, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term

Read more

Ceapro Inc. Confirms Excellent Bioavailability of its New Water Soluble Chemical Complex Coenzyme Q10-Beta Glucan – Positive results obtained from a unique research protocol and surgical methodology – Potential for development of a first-in-class slow-release formulation – Results enable Ceapro’s transition to nutraceutical sector by year endx

EDMONTON, ALBERTA – May 29, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced positive results from a bioavailability study for its Pressurized Gas eXpanded liquid

Read more

Ceapro Inc. to Provide a Corporate Update at Its Annual General and Special Meeting of Shareholders on May 29, 2018

EDMONTON, ALBERTA – May 24, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide

Read more

Ceapro Inc. Reports 2018 First Quarter Results

EDMONTON, ALBERTA – May 17, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the quarter ended March 31, 2018.

Read more

Ceapro Inc. Presents PGX Enabling Technology Case Study at the 12th International Symposium on Supercritical Fluids – Ceapro receives issued European Patent for PGX Technology – Poster presentation on a new PGX-dried chemical complex gum Arabic/CoQ10

EDMONTON, ALBERTA – April 25, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Bernhard Seifried, Ph.D., Ceapro’s Director of Engineering Research and Technology, and

Read more

Ceapro Inc. Provides Corporate Update – Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector over the next 12 months – Data expected from the bioavailability study of CoQ10-beta glucan and results of the avenanthramides in exercise-induced inflammation in Q2 2018

EDMONTON, ALBERTA – April 23, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a summary of 2017 key accomplishments and recent highlights. “We have made

Read more

Ceapro Inc. Reports 2017 Financial Results – Year marked by increased investments in product pipeline and enabling technologies

EDMONTON, ALBERTA – April 20, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve months ended December 31, 2017. Ceapro

Read more

Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute – Beta-glucan project expected to be Ceapro’s first clinical project led by MHI’s Montreal Health Innovations Coordinating Center (MHICC)

EDMONTON, ALBERTA – April 18, 2018 – Ceapro Inc. (TSX-V: CZO), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has established a long-term formal collaboration with the prestigious Montreal Heart Institute (MHI). While

Read more
Page 1 of 1212345...10...Last »